AGGF1 and cardiac hypertrophy: H&E staining showed that AGGF1 therapy reduced cardiac hypertrophy and heart failure in 6-week-old TAC mice, but the therapeutic effect was lost in the presence of the Antago-miR-183-5p inhibitor (Fig. 8a).